Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752113 | 0.92 | GABRP (0.33) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL1752362 | 0.87 | SMN1; SMN2 (0.33) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL3559661 | 0.85 | FFAR4 (0.32) | CHEK1 | |
| SCHEMBL3560242 | 0.84 | GABRP (0.33) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL1752229 | 0.83 | SMN1; SMN2 (0.32) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL1752112 | 0.83 | GABRP (0.34) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL1751712 | 0.83 | GABRP (0.34) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL4962548 | 0.81 | ALDH1A1 (0.31) | — | |
| SCHEMBL1752338 | 0.80 | GABRP (0.39) | SMN1; SMN2GABRPGABRDNR1I2LMNA | |
| SCHEMBL3564170 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968584-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1893581-B1 | SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES | PFIZER LTD (GB) | 2010-01-27 | — | — | EP | disclosed |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7538134-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1893581-A1 | SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES | Pfizer Limited (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20060287365-A1 | Substituted arylpyrazoles | ZOETIS LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2006134468-A1 | SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287365-A1 | Substituted arylpyrazoles | CYP3A4, CYP3A43, CYP4B1 | SMN1; SMN2 2801/4885GABRP 575/4885GABRD 888/4885 |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | SMN1; SMN2 2801/4885GABRP 575/4885GABRD 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.